News & Updates
November 18, 2019
Nanjing, China Nov. 12, 2019 Nanjing CR Medicon Pharmaceutical Technology CO., Ltd., a Gold level member of Oracle PartnerNetwork (OPN) is collaborating with Oracle Health Sciences to expand their current clinical development offerings with drug safety surveillance and pharmacovigilance services from Oracle Argus. CR Medicon is a subsidiary of Pharmaron, a China-based Clinical Research Organization. Oracle Argus is an industry-leading solution for safety case management, […]
October 27, 2019
On September 25-27, 2019, the China Food and Drug International Exchange Center held the 10th China International Conference on Medical Device Supervision and Management (CIMDR) in Suzhou. This conference is aimed to strengthen the exchange of international medical device regulatory regulations and technical specifications, improve the scientific and technical level of the review process, improve device manufacturers’ awareness of compliance, […]
September 1, 2018
To accelerate its progress in biological sample analysis, CR Medicon has built a new bioanalytical laboratory at its Headquarters in Nanjing, China. The laboratory covers an area of more than 1000 square meters and is officially put into operation in May 2018. This new PK Analysis Lab can support a full range of clinical sample bioanalytical services: including all-round advanced analytical […]
August 1, 2018
The 2018 Medidata NEXT China Conference was held in Shanghai on July 12, 2018. CR Medicon and guests gathered together to discuss clinical development technology advancement, exchanged and shared fore-front innovations in life science and technology, and unveiled the future blueprint of clinical research.
July 24, 2018
In order to remove risks and achieve better drug safety results, China’s food and drug supervision authorities have determined to carry out a wave of vigorous verification process to eliminate safety problems before they become public health issues. As the guardian of public drug safety, China’s regulatory authorities deeply understand that if the authenticity, integrity, and standardization issues in clinical data are not resolved, there will be […]